HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2 year follow-up; a Norwegian prospective multicenter study by unknown
RESEARCH ARTICLE Open Access
HIV patients with latent tuberculosis living in a
low-endemic country do not develop active
disease during a 2 year follow-up; a Norwegian
prospective multicenter study
Nadine Durema Pullar1,2*, Harald Steinum3, Johan Nikolai Bruun1,2 and Anne Ma Dyrhol-Riise4,5,6
Abstract
Background: Interferon-γ release assays (IGRA) serve as immunodiagnostics of tuberculosis (TB) infection to identify
individuals with latent TB infection (LTBI) eligible for preventive anti-TB therapy. In this longitudinal study of
HIV-infected LTBI patients we have observed for possible progression to active TB as well as evaluated repeated
IGRA testing in a TB low-endemic setting.
Methods: QuantiFERON TB-Gold In-tube® assay (QFT), TB-SPOT.TB® (TSPOT) and tuberculin skin test (TST) were
performed on 298 HIV-patients recruited from seven out-patient clinics in Norway. Patients with active TB, LTBI
and negative IGRA were followed with repeat QFTs and clinical evaluation over a period of 24 months.
Results: Seven HIV-patients (median CD4 count 270; IQR 50–340) were diagnosed with active TB at inclusion,
all IGRA positive. Sixty-four (21%) HIV-patients (median CD4 count 471; IQR 342–638) were diagnosed with LTBI
and of these 39 (61%) received TB preventive treatment. Neither treated nor untreated HIV-infected LTBI patients
developed active TB during the 24 months. At baseline, the median interferon-γ (INF-γ) level measured by QFT was
3.48 IU/ml (IQR 0.94 – 8.91 IU/ml) for treated LTBI compared to 1.13 IU/ml (IQR 0.47 – 4.25 IU/ml) for untreated LTBI
patients (p = 0.029). The QFT reversion rates were 75% for active TB, 23% for treated LTBI and 44% for untreated LTBI,
whereas the conversion rate for the non-TB group was 7% despite no new TB exposure. There was no significant
difference in the trend of INF-γ levels over time between treated and untreated LTBI patients.
Conclusion: The prevalence of LTBI is high among HIV-patients, but the risk of developing active TB seems to be low
in patients with high CD4 counts in this TB low-endemic setting. In several patients, especially with baseline IFN-γ levels
close to cut-offs, the QFT tests reverted to negative independent of preventive anti-TB treatment indicating possibly
false positive tests. This highlights the importance of defining reliable cut-offs for immunodiagnostic tests and deferring
preventive therapy in selected patients. Randomized studies with longer follow-up time are needed to identify
HIV-patients that would benefit from LTBI treatment in a TB low-endemic setting.
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Background
For the diagnosis of latent tuberculosis infection (LTBI)
the tuberculin skin test (TST) has been replaced or sup-
plemented by interferon-gamma (IFN-γ) release assays
(IGRA) in many tuberculosis (TB) low-endemic coun-
tries due to their simplicity and improved specificity
[1-4]. However, there are limitations to the use of both
IGRAs and TST in the presence of Human Immunodefi-
ciency virus (HIV) infection as both tests can be nega-
tive due to T-cell anergy in patients with low CD4
counts [5-8]. Furthermore, neither IGRA nor TST can
distinguish between latent and active TB, the tests may
be negative in active TB patients or remain positive in
patients previously treated for TB infection [7-9]. Recent
reports have also highlighted the intra-assay variability
and conclude that positive QuantiFERON-TB Gold In-
Tube tests (QFT) with INF-γ levels less than 0.59 IU/ml
should be interpreted cautiously [10]. An alternative cut-
off of 0.70 IU IFN-γ/ml has also been suggested [11].
The predictive value of TST has been documented by
several studies both in TB-endemic and low-endemic
countries [12]. Although, Diel et al. report two year pro-
gression rates of 8-15% for TB among IGRA-positive pa-
tients, data are limited for IGRAs as prognostic markers
in HIV-infected patients [13].
In Norway, 80-90% of TB cases and 60-70% of new
HIV cases occur in immigrants predominantly from
TB-endemic countries [14,15]. Still, there are no surveil-
lance data on HIV/TB co-infections due to confidentiality
considerations prohibiting identifiable registration of HIV
status. In a survey from the period 2005–2010 (unpub-
lished), only 2-7% of active TB and 1-5% of LTBI patients
were confirmed HIV-infected, but 40% and 50% of active
TB and LTBI patients, respectively had not been HIV
tested. Harstad et al’s study of asylum-seekers in Norway
revealed poor follow-up routines for persons at high risk
for TB where only 1% of LTBI cases received preventive
treatment [16].
We have previously reported a prevalence of 26% for a
positive IGRA test from a cross-sectional study of a cohort
of HIV positive patients [17]. Origin from a TB-endemic
country, prior active TB and TB exposure were risk factors
for positive IGRA. Interestingly, our findings indirectly
support the hypothesis of waning of latent TB infection in
a setting of low infectious burden even in HIV patients, as
IGRA prevalence was lower in patients with more than
10 years stay in Norway. We now report prospective data
on the same HIV-infected cohort where we have observed
for possible progression to active TB over two years in
two comparable groups of HIV patients with and without
preventive anti-TB treatment. We have also compared re-
versions and conversions rates for repetitive QFT tests in
the same time-period. Further, we have studied fluctua-
tions of QFT results over time in patients previously




HIV-infected patients were recruited to the study as previ-
ously described [17]. Briefly, background information on
HIV infection and risk factors for TB were collected on
HIV positive individuals over the age of 18 years recruited
from seven out-patient infectious disease clinics in Norway
between January 2009 and October 2010. Information
on previous active TB diagnosed and treated outside of
Norway was based on self-report. Study participants
were followed for two years with QFT and routine blood
samples including CD4 counts. At inclusion, all patients
were clinically examined for active TB, a chest X-ray
was performed and a sputum sample obtained for acid
fast staining and culture. Those with a positive IGRA or
suspected TB infection were further assessed for active
TB with an additional induced sputum sample or bron-
choalveolar lavage (BAL). In selected patients organ spe-
cific scans and biopsies were obtained according to clinical
judgement. Patients were questioned about travel to
TB-endemic countries, possible re-exposure for TB and
new symptoms of active TB between testing points.
A written informed consent was obtained from each
participant. The study was approved by the Regional
Committee for Medical and Health Research Ethics
(REK-Vest) and by the Norwegian Social Science Data
Services (NSD).
Interferon-gamma Release Assays and Tuberculin Skin
Test
The QuantiFERON TB-Gold In-tube® assay (QFT)
(Cellestis Ltd, Qiagen, Chadstone, VIC, Australia) was
performed at baseline and repeated at 3, 6, 12 and
24 months after initiation of therapy in LTBI and active
TB patients and after 12 and 24 months in HIV patients
with no signs of present TB infection. INF-γ levels ≥ 0.35
international units (IU)/ml (TB antigen response minus
nil response) were considered a positive test. Reversion of
a QFT test was defined as a positive QFT test at baseline
that became negative (INF-γ < 0.35 IU/ml) at one of the
subsequent tests, whereas conversions of a QFT test was
defined as a change from baseline negative to positive
QFT at one of the subsequent test points specified.
T-SPOT.TB® (TSPOT), performed according to manu-
facturer instructions (Oxford Immunotec Ltd., Abingdon,
UK) was taken in parallel to QFT only at inclusion in
patients attending one of the participating hospitals
and was not repeated during follow-up. Positive results
were defined as > 7 spot forming units.
A TST by the Mantoux method was administered once
at study start after the IGRA test was taken to avoid the
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possibility of boosting and read after 72 hours (0.1 ml
tuberculin PPD RT23 2 TU, SSI, Copenhagen, DK) [18].
Induration ≥5 mm was considered a positive test according
to guidelines for HIV-infected persons [19].
Definitions of study groups
Active TB diagnosis was given when the presence of M.
tuberculosis in a clinical sample was laboratory con-
firmed by acid-fast bacilli on microscopy, by growth in
culture or by a nucleic acid amplification test. A clinical
case of active TB was defined according to the following
criteria: a positive TST or IGRA and/or signs and symp-
toms compatible with TB (abnormal chest radiograph or
imaging study, or clinical evidence of current disease)
and a completed diagnostic evaluation followed by initi-
ation of efficient treatment with standard anti-TB ther-
apy [20]. LTBI diagnosis at baseline was given to patients
with a positive IGRA (QFT and/or TSPOT) and no indi-
cation of current or previous active TB. Participants with
a prior active TB, which could explain a positive IGRA
and with no signs or symptoms of active TB at baseline,
were classified as prior active TB. Finally, those that had
received preventive TB therapy before entering the study
were defined as prior LTBI. Patients with a negative base-
line IGRA and no previous or current TB infection were
classified as no TB. Preventive treatment for LTBI, consist-
ing of either 6 months of isoniazid or 3 months of rifampi-
cin and isoniazid, was decided and implemented by the
responsible clinician according to national guidelines [2].
Statistical analysis
All analyses were performed using STATA 12 software
(STATA Corporation, College Station, Texas, USA). De-
scriptive data are presented as median (interquartile range
(IQR)), mean or numbers (percentage). Univariate odds
ratios (OR) for risk factors associated with positive IGRA
and TST in patients with prior TB were obtained by logis-
tic regression models. Quantitative QFT trends over time
for LTBI, active TB and prior TB patients were analyzed
using linear mixed models (LMM) with random intercept.
Wilcoxon rank sum test was used to compare PPVs
(estimated by “The Online TST/IGRA interpreter”) be-
tween patient groups.
Results
Diagnosis of tuberculosis infection by IGRA in HIV
patients
A total of 304 HIV-positive patients were enrolled in the
study, however QFT results were missing in six persons
and these were excluded from the final analysis. The
remaining 298 were classified as active TB (N = 7), LTBI
(N = 64), prior active TB (N = 26), prior LTBI (N = 4) and
no TB (N = 197) (Figure 1). Characteristics of the various
HIV groups stratified by origin from TB-endemic versus
low-endemic regions are given in Table 1. Seventy-nine
patients did not show up for administration of the TST
or for reading after 72 hours. The fractions of positive
IGRAs in the various TST strata are shown in Table 2.
Longitudinal QFT testing during treatment of active
tuberculosis in HIV patients
Seven HIV patients were diagnosed with active TB at
enrolment, five with pulmonary TB and two with extra-
pulmonary TB, all with origin from a TB-endemic coun-
try (Table 3). Five patients met laboratory definitions
whereas two had clinical indications of pulmonary TB.
Four had been previously treated for active TB abroad
with a median time since end of treatment of 1.5 years,
and one had developed a multidrug-resistant TB. Induced
sputum for acid fast staining and culture was performed
in all participants to identify active TB diagnosis in pa-
tients possibly missed by the lack of symptoms, a nega-
tive IGRA or negative chest X-rays, but this diagnostic
approach did not reveal additional cases of TB.
All active TB patients tested one or both IGRAs posi-
tive (Tables 1 and 3). Four of the five active TB patients
with available follow-up QFT results were positive at en-
rolment, but only one remained positive after 24 months.
There was a significant reduction of QFT levels already
at 6 months (coeff.-3.10 IU/ml, p = 0.020) and further at
12 months (coeff. -2.59 IU/ml, p = 0.012). The patient
with negative QFT and positive TSPOT at baseline main-
tained QFT negative results at all test points. There was
no significant association between CD4 counts and QFT
level trends over time in active TB patients.
Longitudinal QFT testing during treatment and follow-up
of latent tuberculosis in HIV patients
Sixty-two patients in this cohort were diagnosed with
LTBI according to study definition. Additionally, two
patients with negative QFT and missing TSPOT were
tested during contact tracing of a contagious TB patient
and based on the clinician judgement considered pos-
sibly infected and given preventive TB therapy (TST 0
and 10 mm) (Table 1). Within 6 months of diagnosis, 39
(61%) LTBI patients had started preventive TB treat-
ment, the majority (92%) with rifampicin and isoniazid
for 3 months. Median INF-γ value at baseline for treated
LTBI was 3.48 IU/ml (IQR 0.94 – 8.91 IU/ml) compared
to 1.13 IU/ml (IQR 0.47 – 4.25 IU/ml) for untreated
LTBI patients (p = 0.029). Neither treated nor untreated
LTBI patients developed active TB during the observa-
tion period of 24 months. However, five patients were
lost to follow-up. No participants reported new exposure
to an active TB case during the study period.
One or more longitudinal follow-up QFT was available
for 47 of the 64 LTBI patients (Figure 2). For those
patients with QFT available at both 12 and 24 months
Pullar et al. BMC Infectious Diseases 2014, 14:667 Page 3 of 10
http://www.biomedcentral.com/1471-2334/14/667
(n = 33), consistently positive QFT was seen in 12/17
treated LTBI patients (7 TST+, 2 TST-, 3 missing TST),
1/17 reverted to negative QFT already at 3 months (TST-),
whereas 4/17 reverted at 12 months (3 TST-, 1 TST+),
though one converted back to positive QFT at 24 months
(TST+). In the untreated LTBI group, consistently positive
QFT was seen in 4/16 patients (3 TST+, 1 missing TST),
7/16 reverted and stayed QFT negative during 24 months
of follow-up (4 TST-, 3 missing TST) whereas 4/16 ex-
perienced QFT reversions, but became positive again
at 24 months (3 TST-, 1 TST+). In addition, 1/16 pa-
tient with negative QFT at baseline became positive at
3 months (TST+, TSPOT+).
Baseline IFN-γ levels were generally lower for un-
treated LTBI patients that reverted compared to those
that remained QFT positive at 24 months but this was
not significant (0.56 IU/ml versus 1.49 IU/ml, p > 0.05).
There was no significant difference in the trend of INF-γ
levels (IU/ml) over time between treated and untreated
LTBI patients (Figure 2). In linear mixed models (LMM)
analyses LTBI patients with a positive TST had higher
INF-γ results over time compared to TST negative pa-
tients (coeff 2.887 IU/ml, p < 0.001), irrespective of pre-
ventive therapy (Figure 3). Higher nadir CD4 counts
were also associated with slightly higher INF-γ over time
(coeff. 0.004 IU/ml per cell/μl, p = 0.024). Travel to TB-
endemic countries between QFT testing points had no
significant effect on INF-γ trends over time. The four
LTBI patients from TB low-endemic countries were not
given treatment. In three of these the QFT test reverted
to negative, and the fourth patient experienced a reduc-
tion in INF-γ levels during follow-up.
Applying an IFN-γ cut-off of 0.70 IU/ml at baseline, as
has been suggested [13], 21 of the HIV-patients diag-
nosed with LTBI in our cohort would have tested QFT
negative. However, ten (48%) had other indicators of
LTBI such as recent TB exposure or a positive TSPOT.
Among the untreated LTBI patients with baseline
IFN-γ < 0.70 IU/ml, seven of the nine with available
follow-up results maintained IFN-γ values < 0.70 IU/ml.
Longitudinal QFT testing in HIV-patients previously
treated for active tuberculosis
Thirty-two patients had been treated for active TB before
enrolment in the study. Two patients were considered
re-infected based on reported new TB exposure before
entering the study and were thus classified as LTBI and
4 were diagnosed with new active TB. Ten of the 26
(38%) “prior active TB” patients tested QFT positive at
baseline (Table 1). Among the patients with available
Figure 1 Study design and study groups. QFT = QuantiFERON-TB Gold. TSPOT = T-SPOT.TB. TST = Tuberculin skin test. TB = Tuberculosis.
LTBI = Latent TB infection
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Table 1 Characteristics of HIV-patients according to origin and stages of tuberculosis infection
TB-endemic countries (N = 217) TB low-endemic countries (N = 81)
LTBI Prior TB* Active TB Prior LTBI No TB LTBI Prior TB No TB
(N = 60) (N = 23) (N = 7) (N = 4) (N = 123) (N = 4) (N = 3) (N = 74)
Age
Median (IQR) 37 (31–41) 41 (36–46) 43 (39–48) 45 (37–49) 36 (31–42) 44 (40–47) 50 (43–60) 53 (46–60)
Gender
Female N (%) 36 (60) 11 (48) 3 (43) 2 (50) 87 (71) 2 (50) 1 (67) 19 (26)
Male N (%) 24 (40) 12 (52) 4 (57) 2 (50) 36 (29) 2 (50) 2 (33) 55 (74)
Years of stay in Norway
Median (IQR) 5 (2–8) 7 (3–11) 5 (1–6) 4 (3–5) 7 (4–10) n/a n/a n/a
Years of HIV infection
Median (IQR) 3 (2–7) 8 (3–10) 7 (3–10) 6 (5–8) 6 (3–9) 16 (9–20) 6 (3–23) 6 (3–11)
Nadir CD4 cells/μl
Median (IQR) 270 (170–488) 80 (40–190) 190 (50–290) 92 (81–190) 188 (87–290) 135 (90–180) 101 (100–230) 192 (90–354)
CD4 cells/μl at enrolment
Median (IQR) 472 (342–638) 340 (240–430) 270 (50–340) 541 (442–608) 408 (276–590) 465 (375–595) 320 (310–560) 468 (312–690)
ART at enrolment N (%) 28 (47) 17 (74) 5 (71) 4 (100) 88 (71) 4 (100) 3 (100) 49 (66)
Exposure to TB 16 (27) 1 (4) 2 (29) 2 (50) 8 (6) 0 1 (33) 6 (8)
TST positive (%) 30 (60)1 8 (47)3 1 (25)5 07 10 (10)8 010 1 (50)12 2 (5)14
TST mm (median-IQR) 10 (0–15) 3 (0–15) 0 (0–5) 0 (0–0) 0 0 (0–1) 11 (0–22) 0
QFT positive (%) 56 (93) 9 (35) 6 (86) 1 (25) 0 4 (100) 1 (33) 0
QFT IU/ml (median-IQR) 2.00 (0.56–6.20) 0.34 (0.34–1.88) 6.33 (0.81–10) 10 (10–10) 0.34 0.91 (0.49–5.63) 0.34 (0.34–10) 0.34
TSPOT positive (%) 20 (87)2 6 (50)4 3 (60)6 …. 09 011 013 015
TST/QFT discordance N (%) 22 (44) 5 (29) 2 (50) 0 10 (10) 3 (60) 0 2 (5)
TST-/QFT+ 19 2 2 0 0 3 0 0
TST+/QFT- 3 3 0 0 10 0 0 2
TB: tuberculosis. LTBI: latent TB infection. ART: antiretroviral therapy. QFT: QuantiFERON TB Gold. TSPOT: T-SPOT.TB. n/a: not applicable. *Excludes 2 diagnosed with LTBI and 4 diagnosed with current active TB. 1TST
available in 50 LTBI pasients from TB-endemic countries. 2TSPOT available in 23 LTBI pasients from TB-endemic countries. 3TST available in 17 patients with prior TB from TB-endemic countries. 4TSPOT available in 12
patients with prior TB from TB-endemic countries. 5 TST results available in 4 patients with active TB. 6 TSPOT results available in 5 patients with active TB. 7TST results available in 2 patients with prior LTBI. 8 TST
available in 96 “no TB” patients from TB-endemic countries. 9TSPOT available in 44 “no TB” patients from TB-endemic countries. 10TST available in 3 LTBI pasients from TB low-endemic countries. 11TSPOT available in 2
LTBI pasients from TB low-endemic countries. 12TST available in 2 patients with prior TB from TB low-endemic countries. 13 TSPOT available in 2 patients with prior TB from TB low-endemic countries. 14TST available in



















follow-up QFT, 9/21 patients stayed QFT positive (5 TST+,
2 TST-, 2 missing TST), 9/21 patients with negative base-
line QFT remained negative (5 TST-, 1 TST+, 3 missing
TST) and 3/21 converted from QFT negative to positive
after 12 months (2 TST+, 1 TST-), although one reverted
to negative again at 24 months (TST-). There was no indi-
cation of new TB exposure in any of these patients.
In the univariate analysis high CD4 counts at inclusion
was the only factor associated with persistently positive
QFTs in patients with prior active TB (OR 14.05, 95% CI
1.57-125.55, p = 0.018) and in LMM analysis IFN-γ levels
increased with increasing CD4 counts (coeff. 0.008 IU/ml
per cell/μl, p = 0.003). There was no significant association
between time since treatment and QFT results. Mean
INF-γ values over time were significantly lower in patients
with a previous pulmonary TB (mean 1.42 IU/ml, SD 1.97)
compared to patients with extra-pulmonary TB (mean 3.99,
SD 4.29, p = 0.02).
Longitudinal QFT testing in HIV-patients with negative
baseline IGRA
Follow-up QFT was available in 138 of the197 HIV pa-
tients classified as no TB. Conversion rates to positive
QFT in this group were 7% at 12 months and 4% at
24 months. However, no patients reported exposure to
TB during the study period.
Discussion
This study describes the challenges of LTBI diagnosis
and decision-making regarding preventive TB treatment
in HIV patients in a TB low-endemic country as Norway.
The prevalence of LTBI in our HIV positive cohort was
high with the majority of patients originating from TB-
endemic countries, in line with other studies [5,7,13,21,22].
Still, in our study, with over half of the HIV-patients on
ART, none of the LTBI patients developed active TB
during the 24 months of observation time regardless of
preventive anti-TB treatment.
The lack of a diagnostic gold standard for LTBI leaves
much up to clinicians to decide if the patients should
receive preventive anti-TB therapy. In this study 94% of
LTBI patients received the diagnosis based on a positive
IGRA and 6% on clinical judgement. However, only 61%
of the HIV-infected LTBI patients received preventive
anti-TB treatment, although strongly advised by Norwegian
and international guidelines [2,4]. Poor implementation
of anti-TB preventive treatment is also revealed in the
study among asylum seekers by Harstad et al., where
none of the seven LTBI patients with HIV-infection
were treated [16,23].
According to a Cochrane review, LTBI treatment re-
duces the risk of active TB by 32% in HIV patients [24].
A Swiss HIV Cohort Study reinforced the importance of
preventive treatment in a TB low-endemic setting [12].
In our study, clinicians refrained from treating the few
QFT positive patients from TB low-endemic countries
with no known TB exposure. The majority of these pa-
tients tested negative when QFT was repeated support-
ing a study of US-born HIV patients at low risk for TB
in which 80% with initial positive QFT reverted to nega-
tive when retested after a median time of 40 days indi-
cating false positive primary tests [25]. Also we observed
a high QFT reversion rate of 44% in the untreated LTBI
group. Further, untreated LTBI patients had lower IFN-γ
values compared to treated patients in our study, indi-
cating a tendency for clinicians to make decisions based
on IFN-γ values. Fluctuations of IFN-γ values close to the
cut-off of ≥ 0.35 IU/ml in the QFT assay are described in
several studies supporting suggestions to adjust IFN-γ
cut-off levels [10,11,18,26] and define a borderline inter-
val, for example 0.35 – 0.70 IU/ml [27]. Thus, we advocate
a policy of retesting HIV patients with low INF-γ levels
as well as to consider deferring preventive treatment in
patients expected to have low risk of progression to active
TB infection due to efficient ART [28].
The consequences of not treating LTBI in HIV infec-
tion are difficult to ascertain. Whereas there is an abun-
dance of studies on the risk of progression to active TB
in TST positive patients, data are more limited for IGRA
positive patients [13]. We have not found data to sup-
port that higher IFN-γ levels in HIV infection increases
the risk of developing active TB. The review by Diel
et al. concludes that the positive predictive value (PPV)
for progression to active TB of 3-14% with positive
IGRA is higher than for TST [13]. Still, whereas low
CD4 counts are associated with an increased risk of de-
veloping TB, the risk is less among HIV patients receiv-
ing efficient ART [12]. Our study where none developed
active TB regardless of preventive therapy is in contrast
to the Swiss study were 6.5% of HIV-patients not treated
for LTBI acquired active TB during the follow-up of
52 months [12]. A PPV of 8-10% for progress to active
TB infection in IGRA positive HIV infected patients
within a two years period has also been documented


















<5 56 10 (18) 165 26 (16) 0.81 (0.39-10)
5-10 7 6 (86) 17 8 (47) 7.20 (1.44-10)
11-14 3 1 (33) 12 10 (83) 2.60 (0.57-10)
≥ 15 8 6 (75) 23 16 (70) 4.68 (0.5-10)
TST = Tuberculin skin test. IGRA = Interferon-gamma Release Assay. TSPOT= T-SPOT.
TB. QFT =QuantiFERON-TB Gold. INF-γ= Interferon-gamma .TST results were missing
for 63 negative QFTs, 17 positive QFTs and 1 indeterminate QFT. TST results were
missing for 6 positive TSPOTs, 36 negative TSPOTs and 1 borderline TSPOT.
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Table 3 Demographics and clinical data for HIV patients diagnosed with active TB



















South-east Asia 40 F 6 n/a Yes 302 <20 nd 2.66 nd +/+ - Pulmonary -
East-africa 45 M 6 n/a Yes 340 8750 10 10 + +/+ - Abdominal -
Central-africa 33 F 5 1 Yes 190 70 nd 10 nd +/+ - Lymph node MDR
Central-africa 43 M 3 2 No 480 <20 0 0.62 b.l -/nd + Pulmonary n/a
East-africa 42 F 1 1 No 50 >100000 0 0.34 + -/nd + Pulmonary n/a
East-africa 50 M 1 11 No 50 >100000 0 0.81 - +/nd - Pulmonary -
West-africa 38 M 7 n/a No 270 >100000 nd 10 + +/+ + Pulmonary INH



















from other TB low-endemic countries [29,30]. The fact
that CD4 counts were lower and fewer patients were on
ART in these studies compared to our study could partly
explain these conflicting data. Furthermore, patients
with active TB might have been misclassified as LTBI,
whereas active TB patients were carefully identified at
inclusion in our study.
Tools such as “The online TST/IGRA interpreter” to
assist diagnosis and treatment decisions aim to identify
patients at risk for TB infection [31,32]. Using this algo-
rithm we calculated PPVs for TB infection of 93.2% - 99.9%
for patients classified as LTBI in our cohort with the lowest
PPV calculated for patients from TB low-endemic coun-
tries. HIV-infected with positive TST, negative IGRA and
no history of TB exposure had PPVs for TB infection up
to 95% by this calculator, whereas these patients were not
diagnosed with LTBI in our study, none developed TB
during the two years of follow-up and repeat QFT results
were consistently negative. The calculated annual (7.4-8%)
as well as the overall risk (100%) for active TB was high
for HIV-infected patients. However, the algorithm does
not include ART, CD4 count or negative TSTs making the
algorithm less useful in a HIV positive cohort.
We observed that participants with concordant QFT
and TST results at enrolment maintained higher IFN-γ
levels throughout the observation time of 24 months
[33,34]. This may indicate a stronger and more stable im-
mune response, which may have prognostic significance.
In a recent study conducted in Taiwan, HIV patients with
concordant positive TST and TSPOT results had a
7.8-fold increased risk of developing active TB if left
untreated, suggesting that dual testing is more reliable
[35]. Still, it is of note, for screening purposes TST admin-
istration and reading proved to be difficult in our study
with 27% of participants failing to comply. It is neverthe-
less apparent from our data that the majority of IGRA
positive HIV-patients do not progress to active TB. Prog-
nostic biomarkers to identify those who will progress to
active TB are however lacking. Thus, longitudinal studies
of longer duration are needed to assess TB risk in HIV
patients on efficient ART and high CD4 count.
Figure 2 Quantitative QFT responses over time in HIV patients with LTBI. QFT responses (IU/ml) at baseline (0), 12 months and 24 months
follow-up in LTBI patients receiving preventive TB treatment and in untreated LTBI. There was no significant difference in QFT responses over time
between treated and untreated LTBI patients. QFT = QuantiFERON-TB Gold.
Figure 3 Longitudinal QFT responses in HIV patients with
positive and negative TST. Boxplot showing median (line in box),
interquartal range (box), upper and lower range excluding outliers
(whiskers) and outliers (dots) of QFT responses at baseline, 12 and
24 months in patients with positive QFT and discordant and
concordant TST results. Patients with positive QFT and positive TST
had higher INF-γ responses at baseline and follow-up compared to
patients with positive QFT and negative TST. QFT = QuantiFERON-TB
Gold. TST = Tuberculin skin test.
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Our study from a TB low-endemic setting where only
61% received preventive treatment made it possible to
analyze fluctuations in QFT over time and compare
treated and untreated IGRA positive patients as no pa-
tients reported TB re-exposure during follow-up. There
was no significant difference in QFT over time in treated
or untreated LTBI patients and travel to TB-endemic
countries did not have an impact on QFT results. Higher
nadir CD4 counts but not CD4 count during follow-up
were significantly associated with higher IFN-γ levels
in repeated QFT and reflect the effect of immune sup-
pression upon IFN-γ responses. There was a signifi-
cant reduction in IFN-γ levels during active TB
treatment, but too few active TB patients to conclude.
Other studies have also observed a decline in IFN-γ
levels during TB treatment, but most studies conclude
that QFT and TSPOT are unreliable biomarkers of
treatment efficacy [36-40].
Four of the seven patients diagnosed with new active
TB in our study were previously treated for active TB,
including one patient that developed multidrug-resistant
TB. This illustrates the importance of full clinical evalu-
ation in HIV patients with a prior active TB, particularly
if the prior treatment and follow-up is unknown. Never-
theless, the fact that IGRAs may stay positive in patients
who have previously been adequately treated and cured
for active TB is a major obstacle to the use of IGRA to
monitor treatment efficacy [5,7,23]. In our study 38% of
patients previously treated for TB had positive QFT.
Interestingly, higher CD4 counts was the only factor as-
sociated with persistently positive QFT which may re-
flect higher numbers of circulating TB-antigen specific
effector T-cells. Furthermore, higher INF-γ values over
time were observed in patients with previous extra-
pulmonary TB compared to pulmonary TB, suggesting
that a stronger T-cell response is retained after success-
ful treatment in this group [41].
The main limitation of our study is the inadequate
QFT retesting due to logistic problems that limits evalu-
ation of QFT dynamics over time. Furthermore, the low
number of active TB cases precludes adequate analysis of
test performances during therapy in this patient group.
Conclusion
IGRAs seem to be the most useful screening test for
LTBI in HIV infection in our TB low-endemic clinical
setting as the TST was hampered by poor attendance
and 16-18% of IGRA positive patients tested TST negative.
The LTBI prevalence among HIV patients from TB-
endemic countries was high. Still, LTBI treatment imple-
mentation was low as HIV patients with low baseline IFN-γ
results were generally not given treatment. Neither
treated nor untreated HIV patients with LTBI, the ma-
jority on ART, developed active TB during the two years
of observation time. In both groups there were rever-
sions and conversions of QFT tests and QFT proved to
be unreliable in monitoring LTBI treatment efficacy.
Fluctuations of INF-γ levels close to the established cut-
offs for the QFT-test also justify that retesting and
follow-up without preventive treatment is appropriate
for selected HIV patients. High CD4 count and positive
TST was associated with higher IFN-γ over time and
may indicate persistence of strong immune responses,
which may have prognostic implications. Still, randomized
longitudinal studies are needed to adequately identify HIV
patients that would benefit from LTBI treatment in a TB
low-endemic setting.
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